HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Achieving pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) is linked to better outcomes. HER2-positive status independently predicts pCR, especially with targeted therapy, and Ki67 changes after NAC indicate improved survival.
Area Of Science
- Oncology
- Medical Research
Background
- Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) is associated with improved prognosis.
- Identifying predictive indicators for pCR and understanding the impact of IHC marker conversion post-NAC are crucial for optimizing treatment strategies in locally advanced breast cancer (LABC).
Purpose Of The Study
- To investigate the correlation between clinicopathologic parameters and NAC outcomes in LABC patients to identify pCR predictors.
- To examine the conversion of immunohistochemistry (IHC) markers after NAC and its prognostic significance in BC patients.
Main Methods
- Univariate and multivariate analyses of clinicopathological parameters in 126 LABC patients.
- Kaplan-Meier (KM) curves and log-rank tests for survival analysis.
- Difference and consistency tests for IHC marker conversion post-NAC.
Main Results
- Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and molecular subtypes were associated with pCR in univariate analysis.
- HER2 positivity was an independent predictor of pCR. HER2-positive patients receiving NAC with targeted therapy showed higher pCR rates.
- Changes in Ki67 expression post-NAC correlated with longer overall survival (OS) and disease-free survival (DFS).
Conclusions
- HER2-positive status is an independent predictor of pCR in LABC patients, with combined NAC and targeted therapy improving pCR rates.
- Alterations in IHC markers, particularly Ki67, after NAC can predict a better prognosis for BC patients, including those with triple-negative breast cancer (TNBC).
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
